One of the most widely respected COVID-19 case models forecasts 2.8 million deaths by the end of the year. That means a sharp acceleration in deaths over the next three and a half months.
After Satsuma Pharmaceuticals reported disappointing late-stage results from its migraine treatment, and its shares were absolutely crushed Thursday morning.Â
The FDA has approved Innoviva's treatment of asthma and for patients with chronic obstructive pulmonary disease, the company announced, giving shares a boost early Thursday.
Practically any biotech company attempting almost anything COVID-19 related has seen massive gains. However, there is likely more to come for the rest of the year and into next year. These five stocks could…
iBio has announced that it has selected a vaccine to advance for the prevention of infection by the coronavirus that causes COVID-19.
There is no cure for mesothelioma, but some companies are looking for better ways to treat the disease.
Intra-Cellular Therapies was one of the biggest winners on Wednesday after the company announced positive results from its late-stage clinical trial in patients with bipolar disorder.
A key update from the FDA on its treatment for relapsed/refractory multiple myeloma boosted Precision BioSciences shares early on Wednesday.
Co-Diagnostics announced Tuesday that it has entered into an agreement with Arches Research to expand Arches' COVID-19 testing services using Co-Diagnostics’ test kit.
The race for finding the COVID-19 vaccine is in full swing, and it has just seen one team move ahead of the others. Before getting into an actual prediction basis for knowing which vaccine…
Kamada has announced initial interim results from its ongoing midstage coronavirus study of its treatment of COVID-19 patients with pneumonia.
Corbus Pharmaceuticals has reported that its systemic sclerosis study failed to reach the endpoints, and investors were not pleased.
On Thursday, Akebia Therapeutics Inc. (NASDAQ: AKBA) announced topline results from the Phase 3 PRO2TECT studies evaluating the safety and efficacy of vadadustat in chronic kidney disease (CKD). Shares were crushed afterward. This is…
Auris Medical has reported topline data from its Phase 2 Travers trial with intranasal betahistine in vertigo.
America and the rest of the world is getting ready for a vaccine that will help protect public health against the COVID-19 pandemic. The societal impact of the coronavirus has changed many lives, and…
